{
    "organizations": [],
    "uuid": "487828a3c8787900118792a16b1897e092088e14",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sierra-oncology-significantly-expa/brief-sierra-oncology-significantly-expands-clinical-development-program-idUSFWN1QH0OO",
    "ord_in_thread": 0,
    "title": "BRIEF-Sierra Oncology Significantly Expands Clinical Development Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 27, 2018 / 12:29 PM / in 13 minutes BRIEF-Sierra Oncology Significantly Expands Clinical Development Program Reuters Staff * SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM * SIERRA ONCOLOGY INC - ADDING NEW SRA737 MONOTHERAPY COHORT FOR CCNE1-DRIVEN OVARIAN CANCER * SIERRA ONCOLOGY INC - SRA141 IND SUBMISSION PLANNED IN H2 2018 * SIERRA ONCOLOGY - ONGOING SRA737 CLINICAL STUDIES EXPANDED TO TARGET AGGREGATE ENROLLMENT OF 200 PATIENTS ACROSS TEN CANCER INDICATIONS * SIERRA ONCOLOGY - TO INITIATE PHASE 1B/2 TRIAL IN Q4 TO EVALUATE SRA737 WITH ZEJULA TO TREAT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER * SIERRA ONCOLOGY - EXPANDING NUMBER OF ACTIVE SITES RECRUITING PATIENTS INTO SRA737-01 PHASE 1/2 MONOTHERAPY TRIAL FROM 3 TO 15 * SIERRA ONCOLOGY - MAJORITY OF REPORTED ADVERSE EVENTS IN SRA737-02 PHASE 1/2 LDG COMBINATION TRIAL HAVE BEEN GRADE 1 OR GRADE 2 IN SEVERITY * SIERRA ONCOLOGY - ONLY ONE GRADE 3 TREATMENT RELATED AE (NEUTROPENIA) WAS OBSERVED, AT 40 MG SRA737/300 MG/M(2) GEMCITABINE Source text for Eikon: Further company coverage:",
    "published": "2018-02-27T14:26:00.000+02:00",
    "crawled": "2018-02-27T14:47:48.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "oncology",
        "significantly",
        "expands",
        "clinical",
        "development",
        "program",
        "reuters",
        "staff",
        "sierra",
        "oncology",
        "significantly",
        "expands",
        "clinical",
        "development",
        "program",
        "sierra",
        "oncology",
        "inc",
        "adding",
        "new",
        "sra737",
        "monotherapy",
        "cohort",
        "ovarian",
        "cancer",
        "sierra",
        "oncology",
        "inc",
        "sra141",
        "ind",
        "submission",
        "planned",
        "h2",
        "sierra",
        "oncology",
        "ongoing",
        "sra737",
        "clinical",
        "study",
        "expanded",
        "target",
        "aggregate",
        "enrollment",
        "patient",
        "across",
        "ten",
        "cancer",
        "indication",
        "sierra",
        "oncology",
        "initiate",
        "phase",
        "trial",
        "q4",
        "evaluate",
        "sra737",
        "zejula",
        "treat",
        "metastatic",
        "prostate",
        "cancer",
        "sierra",
        "oncology",
        "expanding",
        "number",
        "active",
        "site",
        "recruiting",
        "patient",
        "phase",
        "monotherapy",
        "trial",
        "sierra",
        "oncology",
        "majority",
        "reported",
        "adverse",
        "event",
        "phase",
        "ldg",
        "combination",
        "trial",
        "grade",
        "grade",
        "severity",
        "sierra",
        "oncology",
        "one",
        "grade",
        "treatment",
        "related",
        "ae",
        "neutropenia",
        "observed",
        "mg",
        "gemcitabine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}